Refractory post-surgical cystoid macular edema managed following suprachoroidal microcatheterization and delivery of triamcinolone

BMC Ophthalmology

Research

Matthieu Goncerut¹  Marc D. de Smet²  Ron Yamamoto³  Friedrich Asmus³ 

[1] Helvetia Retina Associates, Lausanne, Switzerland;Helvetia Retina Associates, Lausanne, Switzerland;New York Eye and Ear Infirmary of Mt Sinai, Icahn School of Medicine, New York City, NY, USA;Oxular Ltd, Oxford, UK;

关键词: Microcatheterization;    CME;    Drug visualization;    Infrared;    Macular edema;    OCT;    Posterior;    Steroid;    Suprachoroidal;   

DOI  :  10.1186/s12886-023-03110-0

 received in 2023-06-13, accepted in 2023-08-22,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundPost-surgical macular edema (ME) is a common cause of prolonged visual impairment. Here we report on the feasibility and clinical outcomes from the use of a novel suprachoroidal microcatheter to treat post-surgical chronic ME by the posterior suprachoroidal placement of a triamcinolone acetonide (TA) suspension.MethodsTwo patients were catheterized with the Oxulumis suprachoroidal delivery system on two separate occasions starting 5 and 10 mm posterior to the limbus. The catheter only remains in the suprachoroidal space for the time of the drug administration. Visual acuity and spectral domain optical coherence tomography (SD-OCT) changes were followed over several weeks to months to determine the duration of ME resolution.ResultsSuprachoroidal microcatheterization for posterior delivery of triamcinolone was possible in all attempts using the illuminated Oxulumis catheter. No reflux, scleral or choroidal trauma was observed. There was no intraocular pressure rise during the follow-up period. The triamcinolone deposit was visible on infrared imaging and on SD-OCT a choroidal elevation was visible. Both progressively disappeared over time. A rapid resolution of ME associated with improved vision was observed following each injection for 3 to 7 months with a TA dose of 2.4 mg or 4 mg.ConclusionsIn these patients with poorly responsive ME, posterior suprachoroidal TA led to a visible suprachoroidal drug deposit and prolonged visual improvement. The Oxulumis microcatheterization device performed as expected and was not associated with any complications.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

12888_2023_5172_Article_IEq7.gif

13690_2023_1170_Article_IEq81.gif

Fig. 3

Fig. 5